» Articles » PMID: 12595345

Divergent Roles of Angiotensin II AT1 and AT2 Receptors in Modulating Coronary Microvascular Function

Overview
Journal Circ Res
Date 2003 Feb 22
PMID 12595345
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Angiotensin II (Ang II) is a potent vasoconstrictor in the peripheral circulation and has been implicated in many cardiovascular diseases associated with elevated oxidative stress. However, its direct vasomotor action and its linkage to oxidative stress-induced vascular dysfunction in the coronary microcirculation remain elusive. In this study, we directly assessed the vasomotor action of Ang II in isolated porcine coronary arterioles and also examined whether Ang II can modulate endothelium-dependent nitric oxide (NO)-mediated dilation via superoxide production. Ang II evoked vasoconstriction at a low concentration (1 nmol/L) and dilations at higher concentrations (>10 nmol/L). Ang II type 1 (AT(1)) receptor antagonist losartan abolished vasoconstriction, whereas Ang II type 2 (AT(2)) receptor antagonist PD 123319 eliminated vasodilation. Adenosine stimulated a significant arteriolar NO production and dilation. NO synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA) abolished stimulated NO production and attenuated vasodilation. Pretreating vessels with a subvasomotor concentration of Ang II (0.1 nmol/L, 60 minutes) mimicked inhibitory effects of L-NMMA. Ang II-mediated inhibition was not observed in the presence of L-NMMA or after endothelial removal but was prevented by losartan, superoxide scavenger TEMPOL, or NADPH oxidase inhibitor apocynin. Dihydroethidium staining showed that Ang II elicited losartan- and TEMPOL-sensitive superoxide production in arterioles. These results demonstrate that Ang II evokes AT1 receptor-mediated vasoconstriction and AT2 receptor-mediated vasodilation of coronary arterioles. Ang II at a subvasomotor level impairs endothelium-dependent NO-mediated dilation attributable to elevated superoxide production via AT1 receptor activation of NADPH oxidase. These data may partly explain the impaired coronary flow regulation in heart diseases associated with an upregulated renin-angiotensin system.

Citing Articles

Endothelial FOSL1 drives angiotensin II-induced myocardial injury via AT1R-upregulated MYH9.

Zhao W, Qian Y, Zhang Y, Yang A, Cao J, Qian H Acta Pharmacol Sin. 2024; .

PMID: 39592734 DOI: 10.1038/s41401-024-01410-9.


Molecular mechanisms of endothelial dysfunction in coronary microcirculation dysfunction.

Zhang Z, Li X, He J, Wang S, Wang J, Liu J J Thromb Thrombolysis. 2023; 56(3):388-397.

PMID: 37466848 DOI: 10.1007/s11239-023-02862-2.


Should Renal Inflammation Be Targeted While Treating Hypertension?.

Chaudhari S, Pham G, Brooks C, Dinh V, Young-Stubbs C, Shimoura C Front Physiol. 2022; 13:886779.

PMID: 35770194 PMC: 9236225. DOI: 10.3389/fphys.2022.886779.


Angiotensin II-induced endothelial dysfunction: Impact of sex, genetic background, and rho kinase.

Kinzenbaw D, Langmack L, Faraci F Physiol Rep. 2022; 10(11):e15336.

PMID: 35681278 PMC: 9184751. DOI: 10.14814/phy2.15336.


Activation of Coronary Arteriolar PKCβ2 Impairs Endothelial NO-Mediated Vasodilation: Role of JNK/Rho Kinase Signaling and Xanthine Oxidase Activation.

Thengchaisri N, Hein T, Ren Y, Kuo L Int J Mol Sci. 2021; 22(18).

PMID: 34575925 PMC: 8471475. DOI: 10.3390/ijms22189763.